Related references
Note: Only part of the references are listed.Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma A Multicenter Study From China
Xin-Fei Xu et al.
JAMA SURGERY (2019)
Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group
Alessandro Vitale et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2018)
Early disseminated recurrence after liver resection in solitary hepatocellular carcinoma
Jong Man Kim et al.
ANNALS OF SURGICAL TREATMENT AND RESEARCH (2018)
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
Tim Meyer et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Use of Transarterial Chemoembolization (TACE) and Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: US Regional Analysis of the GIDEON Registry
Jean-Francois H. Geschwind et al.
LIVER CANCER (2016)
Salvage Versus Primary Liver Transplantation for Early Hepatocellular Carcinoma: Do Both Strategies Yield Similar Outcomes?
Prashant Bhangui et al.
ANNALS OF SURGERY (2016)
Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy
Yusuke Yamamoto et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: Final results of the START trial
Yee Chao et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review of the Literature
O. Abdel-Rahman et al.
DIGESTIVE DISEASES AND SCIENCES (2013)
Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up
C. Verslype et al.
ANNALS OF ONCOLOGY (2012)
Transarterial Chemoembolization Plus Sorafenib: A Sequential Therapeutic Scheme for HCV-Related Intermediate-Stage Hepatocellular Carcinoma: A Randomized Clinical Trial
Domenico Sansonno et al.
ONCOLOGIST (2012)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
Liver Resection for Transplantable Hepatocellular Carcinoma Long-Term Survival and Role of Secondary Liver Transplantation
Daniel Cherqui et al.
ANNALS OF SURGERY (2009)
Prognostic factors and optimal treatment strategy for intrahepatic nodular recurrence after curative resection of hepatocellular carcinoma
Gi-Hong Choi et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis
Hashem B. El-Serag et al.
GASTROENTEROLOGY (2007)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma
Jung Ho Park et al.
AMERICAN JOURNAL OF SURGERY (2006)
Scattered and rapid intrahepatic recurrences after radio frequency ablation for hepatocellular carcinoma
Kazuhiro Kotoh et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
A Trotti et al.
SEMINARS IN RADIATION ONCOLOGY (2003)
Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma
M Minagawa et al.
ANNALS OF SURGERY (2003)
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:: a randomised controlled trial
JM Llovet et al.
LANCET (2002)
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
CM Lo et al.
HEPATOLOGY (2002)
Share Paper
